IgA antibodies specific for HAV have been shown to enhance both hepatocellular uptake and transcytosis of HAV (14, 34), but these antibodies develop late in the course of hepatitis A and are associated with a decrease, not an increase, in fecal shedding of virus (4, 35, 36). This evidence concerns the gene CD79A and hepatitis A virus infection.